Keep updated on EptivA Therapeutics activities.
EPTIVA THERAPEUTICS ANNOUNCES LICENSING AGREEMENT FOR EXCLUSIVE WORLDWIDE RIGHTS TO CLINICAL STAGE PERSONALIZED ANALGESICS® ASSET
OXFORD, 1st August 2022 — Eptiva Therapeutics Ltd., the first company to apply a precision medicine approach to developing new pain therapeutics, announces today that they have signed a licensing agreement with To Better Days Ltd. for worldwide exclusive rights to develop and commercialize their proprietary transdermal cholecalciferol patch in prescription indications.
EptivA Therapeutics and Bayer enter into a contract research agreement
EptivA Therapeutics will utilize their proprietary Personalized Analgesics® research platform on Bayer’s research targets.
EptivA Therapeutics will present at SMi's 22nd Pain Therapeutics Conference in London
EptivA Therapeutics CEO & Founder Mark Field will present at SMi's 22nd Pain Therapeutics Conference in London 4 - 5 May 2022 to discuss Personalized Analgesics® research and how it represents the first precision medicine approach to pain.
More news coming soon....